SEC Form 4 · accession 0001062993-18-003555
BIOSPECIFICS TECHNOLOGIES CORP · BSTC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Paul Gitman
Director
Period of report
Aug 23, 2018
Accepted (ET)
Aug 27, 2018 · 8:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875622
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par valueF1 | Aug 23, 2018 | S | 5,425 | $51.2748 | D | 46,400 | D | |
| Common Stock, $0.001 par valueF2 | Aug 24, 2018 | S | 6,400 | $51.0878 | D | 40,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The selling price of $51.2748 is reflective of the weighted average sale price of all transactions reported on this line. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F2The selling price of $51.0878 is reflective of the weighted average sale price of all transactions reported on this line. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.